AstraZeneca enlists an upstart China biotech partner in the wake of an R&D setback
One of the newly created biotech upstarts in China has tied up with a Big Pharma backer on a discovery deal targeted at hypercholesterolemia and metabolics.
The China biotech is Cholesgen, and it’s unlikely you’ve ever heard much about it.
The fledgling biotech booted up with its $14 million launch round pieced together in early 2021 from a broad syndicate that included AZ-CICC, AstraZeneca’s $1 billion investment fund created four years ago as the pharma giant looked to grow its Shanghai R&D ops and partner up with a new generation of discovery groups taking root in the giant Chinese market.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.